European Institute of Oncology: Neuroendocrine Tumors trials

The registry lists 12 Neuroendocrine Tumors studies with European Institute of Oncology as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 2 4No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine NeoplasmsRecruitingNCT06785597
• Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small BowelRecruitingNCT06773624Not applicable
• Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 PatientsRecruitingNCT06343428
• YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.RecruitingNCT06337760
• Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic ImplicationsRecruitingNCT06321692Not applicable
• Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe StudyRecruitingNCT05554003Phase 2
• Registry on NEN Patients and COVID-19RecruitingNCT04444401
• Neoadjuvant PRRT With Y-90-DOTATOC in pNETTerminatedNCT05568017Phase 2
• 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NETActive, not recruitingNCT05448157
• Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)Status unknownNCT04720391
• Beta- Probe and Surgery in GEP NET: Evaluation of a New ProbeCompletedNCT04296149Phase 2
• A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With EverolimusCompletedNCT02305810Phase 2